One-year treatment with abatacept delays progression to rheumatoid arthritis for up to 4 years among at-risk patients.

People receiving a year of abatacept (Orencia) injections had onset of rheumatoid arthritis postponed by up to four years, researchers reported Jan. 20 in The Lancet Rheumatology. Currently, no ...

Patients with rheumatoid arthritis (RA) who also had chronic obstructive pulmonary disease (COPD) had no increased risk of serious respiratory complications when treated with abatacept (Orencia), a ...

High-risk patients in the the study were seropositive, had arthralgia, and showed signs of inflammation on MRI, according to the presentation at the American College of Rheumatology (ACR) virtual ...

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

Philip Day loved playing soccer so much that the 35-year-old software engineer founded a website -- FootballMatcher.com -- to help people connect for pickup games. The fun went on pause when Day ...

Please provide your email address to receive an email when new articles are posted on . A recent study on the benefits of abatacept for patients with moderate-to-severe Crohn’s disease or ulcerative ...

In this double-blind phase 2 study, patients with undifferentiated arthritis (defined by ≥ 2 swollen joints but not fulfilling ACR RA criteria) of < 18 months' duration and anti-cyclic citrullinated ...

"Real-world" data from the Swedish Rheumatology Quality register show that patients with rheumatoid arthritis (RA) for whom abatacept (Orencia, Bristol-Myers Squibb) is the first biologic ...

Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With ...

Efficacy and Safety Data Further Supporting Use of ORENCIA in New-to-Biologic Patients with Moderate to Severe Rheumatoid Arthritis Added to Product Labeling NEW YORK--(BUSINESS WIRE)--Bristol-Myers ...

The between-group difference in restricted mean arthritis-free survival time seen at 2 years persisted at 4 years.